Bookmark this page — the only place tracking real acceptance speed, FWCI and field-normalized citation data for this journal.

Journal decision profile

Experimental Hematology & Oncology

Medicine · Immunology and Microbiology

BioMed CentralUnited KingdomeISSN 2162-3619

Visit homepage

12.92026 metrics scoreOpenAlex · CC0

98dmedian speedlatest 100 articles

$2,990publishing cost*verify with journal

Journal Metrics Score

Journal Metrics ScoreThe visible value is the 2026Journal Metrics Score: citations in the most recent complete year to the journal's works from the two prior years, divided by the number of those works — from OpenAlex open data (CC0).

2026

12.9

Journal Metrics Score 2026 · 2021–2024 window citedness 12.48.

Speed

SpeedMedian calendar days from manuscript received to accepted. It includes revision time and is not the journal's time to first decision.

PUBMED

98 days

Submission → acceptance · median · 100/100 recent articles.

APC / cost*

APC / cost*Costs are indicative and may exclude taxes, waivers, society discounts, or article-type charges. Always verify the journal's official website.

VERIFY

$2,990

Indicative journal-level APC. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

At a glance

Journal decision profile

A visual summary for comparison—not a single black-box star rating.

Relative profile

Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible

Metrics Score

Metrics ScoreThe 2026 Journal Metrics Score, normalized within a comparable journal cohort for this preview.

12.92026 · OPENALEX

Source output rank

Source output rankLifetime journal-wide output rank among OpenAlex sources associated with the journal’s leading topic.

#206 / 665LIFETIME OUTPUT

Highly cited papers

Highly cited papersRecent works in the global top 10% after normalization by work type, year, and subfield.

46.5%FIELD-NORMALIZED TOP 10%

Field-normalized impact

Field-normalized impactMedian FWCI, where 1.0 is the expected citation level for comparable work.

2.20MEDIAN FWCI

Review speed

Review speedMedian submission-to-acceptance time from qualified PubMed records.

98 daysMEDIAN

Recent output

Recent outputAverage annual publication volume across the complete analysis window.

99 / yr2021–2024 AVG

Cost efficiency

Cost efficiencyNo score is assigned without a reliable journal-level cost.

—NOT SCORED

Field-normalized top 10% share46.5%

184 of 396 works · same type, year & subfield

Field-normalized top 1% share6.1%

24 works · same type, year & subfield

Median FWCI2.20×

Above field-year expectation

Source output rank#206

of 665 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 2.20, so its typical recent paper runs about 120% above its field benchmark.

What does Top 10% Share mean?

46.5% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Submission to acceptance time (publication speed)

Among 100 recent articles with complete PubMed dates, the median time from received to accepted was 98 days. It includes revisions and is not the journal's time to first decision.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

12016

322017

322018

322019

372020

602021

1082022

1052023

1232024

1412025

Recent work-type mix

396 OpenAlex works · 2021–2024

Article96%

Erratum2%

Review1.5%

Conference abstract0.5%

OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.

Fit signals

Topics and research coverage

OpenAlex topics show the research communities this journal serves.

Leading OpenAlex topics

2021–2024 works

CAR-T cell therapy research51

Acute Myeloid Leukemia Research27

Immune cells in cancer16

Cancer Immunotherapy and Biomarkers15

RNA modifications and cancer14

Lymphoma Diagnosis and Treatment13

Immune Cell Function and Interaction12

Epigenetics and DNA Methylation9

Chronic Lymphocytic Leukemia Research7

Ubiquitin and proteasome pathways7

Methodology: OpenAlex snapshot 2026-08-09. FWCI, percentile badges, topics, and type mix use 396 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.